390 related articles for article (PubMed ID: 29203271)
1. Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.
Michael JV; Goldfinger LE
Semin Cancer Biol; 2019 Feb; 54():121-130. PubMed ID: 29203271
[TBL] [Abstract][Full Text] [Related]
2. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.
Kattan WE; Hancock JF
Biochem J; 2020 Aug; 477(15):2893-2919. PubMed ID: 32797215
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Approaches to RAS Mutation.
Scott AJ; Lieu CH; Messersmith WA
Cancer J; 2016; 22(3):165-74. PubMed ID: 27341593
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
6. Drugging the undruggable RAS: Mission possible?
Cox AD; Fesik SW; Kimmelman AC; Luo J; Der CJ
Nat Rev Drug Discov; 2014 Nov; 13(11):828-51. PubMed ID: 25323927
[TBL] [Abstract][Full Text] [Related]
7. Drugging RAS: Know the enemy.
Papke B; Der CJ
Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
[TBL] [Abstract][Full Text] [Related]
8. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
9. Biology, pathology, and therapeutic targeting of RAS.
Rhett JM; Khan I; O'Bryan JP
Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
[TBL] [Abstract][Full Text] [Related]
10. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox AD; Der CJ; Philips MR
Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
[TBL] [Abstract][Full Text] [Related]
11. Direct inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith R; O'Bryan JP
Semin Cancer Biol; 2019 Feb; 54():138-148. PubMed ID: 29248537
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of K-Ras plasma membrane localization.
Cho KJ; van der Hoeven D; Hancock JF
Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
[TBL] [Abstract][Full Text] [Related]
13. Blocking Ras inhibition as an antitumor strategy.
Marín-Ramos NI; Ortega-Gutiérrez S; López-Rodríguez ML
Semin Cancer Biol; 2019 Feb; 54():91-100. PubMed ID: 29409706
[TBL] [Abstract][Full Text] [Related]
14. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting of RAS: Recent success with direct inhibitors.
O'Bryan JP
Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101
[TBL] [Abstract][Full Text] [Related]
16. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Ras signaling and function by plasma membrane microdomains.
Goldfinger LE; Michael JV
Biosci Trends; 2017 Mar; 11(1):23-40. PubMed ID: 28179601
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol and Sphingolipid Enriched Lipid Rafts as Therapeutic Targets in Cancer.
Codini M; Garcia-Gil M; Albi E
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450869
[TBL] [Abstract][Full Text] [Related]
19. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies to target RAS-mutant cancers.
Ryan MB; Corcoran RB
Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
